EGFR and non-small cell lung carcinoma: Erlotinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) that is a first‐line treatment for advanced NSCLC in patients harbouring activated EGFR mutations (ie, exon 19 deletion or exon 21 L858R mutation).